JSC PHARMSTANDARD ANNOUNCES FINANCIAL RESULTS FOR 2004, 2005 AND H1 2006

05.12.2006

5 December 2006. Moscow – JSC PHARMSTANDARD announces its audited financial results for 2004 and 2005 and reviewed financial results for H1 2006 in accordance with International Financial Reporting Standards (IFRS).

 KEY FINANCIAL INDICATORS

 

6 months comparison[1]

 

Year to year comparison[2]

RUR thousand

6months 2006

6months 2005

Variance %

 

2005

2004

Variance %

Sale of goods

2 916 686

2 417 194

21%

 

5 684 824

3 945 684

44%

Pharmaceutical products

2 314 878

1 926 723

20%

 

4 635 033

3 901 900

19%

% of total sales

79,4%

79,7%

 

 

81,5%

98,9%

 

Medical equipment and disposables

549 048

462 104

19%

 

1 011 120

0

-

% of total sales

18,8%

19,1%

 

 

17,8%

0,0%

 

Other sales

52 760

28 367

86%

 

38 671

43 784

(12%)

% of total sales

1,8%

1,2%

 

 

0,7%

1,1%

 

Gross profit

1 683 704

1 206 632

40%

 

3 177 722

1 725 703

84%

% of total sales

57,7%

49,9%

 

 

55,9%

43,7%

 

SG&A expenses

685 703

666 648

3%

 

1 512 778

1 053 596

44%

% of total sales

23,5%

27,6%

 

 

26,6%

26,7%

 

Profit before income tax

896 523

416 775

115%

 

1 443 697

437 315

230%

% of total sales

30,7%

17,2%

 

 

25,4%

11,1%

 

Profit for the period

646 944

302 166

114%

 

1 019 323

319 596

219%

% of total sales

22,2%

12,5%

 

 

17,9%

8,1%

 

EBITDA[3]

1 017 067

550 097

85%

 

1 719 709

583 117

195%

% of total sales

34,9%

22,8%

 

 

30,3%

14,8%

 

 


[1] The data is derived from unaudited interim IFRS consolidated financial statements for the six months period ended 30 June 2005 and 2006.

[2] The data is derived from audited IFRS consolidated financial statements for 2004 and 2005.
[3] EBITDA is defined as profit for the period before income tax expense, finance costs, depreciation and amortisation. 

Press release in MS Word


Back Print out